Seres Therapeutics (MCRB) Competitors $13.99 -0.27 (-1.89%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$13.95 -0.04 (-0.29%) As of 08/1/2025 05:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MCRB vs. ERAS, MBX, CGEM, KOD, PGEN, PRTC, RGNX, SVRA, KMDA, and CMPXShould you be buying Seres Therapeutics stock or one of its competitors? The main competitors of Seres Therapeutics include Erasca (ERAS), MBX Biosciences (MBX), Cullinan Therapeutics (CGEM), Kodiak Sciences (KOD), Precigen (PGEN), PureTech Health (PRTC), REGENXBIO (RGNX), Savara (SVRA), Kamada (KMDA), and Compass Therapeutics (CMPX). These companies are all part of the "pharmaceutical products" industry. Seres Therapeutics vs. Its Competitors Erasca MBX Biosciences Cullinan Therapeutics Kodiak Sciences Precigen PureTech Health REGENXBIO Savara Kamada Compass Therapeutics Erasca (NASDAQ:ERAS) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, media sentiment, risk, analyst recommendations, earnings, institutional ownership, valuation and dividends. Does the media favor ERAS or MCRB? In the previous week, Seres Therapeutics had 1 more articles in the media than Erasca. MarketBeat recorded 2 mentions for Seres Therapeutics and 1 mentions for Erasca. Erasca's average media sentiment score of 0.15 beat Seres Therapeutics' score of 0.13 indicating that Erasca is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Erasca 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Seres Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders hold more shares of ERAS or MCRB? 67.8% of Erasca shares are held by institutional investors. Comparatively, 59.3% of Seres Therapeutics shares are held by institutional investors. 14.4% of Erasca shares are held by company insiders. Comparatively, 4.7% of Seres Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has more risk & volatility, ERAS or MCRB? Erasca has a beta of 1.05, indicating that its stock price is 5% more volatile than the S&P 500. Comparatively, Seres Therapeutics has a beta of 2.89, indicating that its stock price is 189% more volatile than the S&P 500. Do analysts rate ERAS or MCRB? Erasca currently has a consensus target price of $4.57, suggesting a potential upside of 228.88%. Seres Therapeutics has a consensus target price of $73.67, suggesting a potential upside of 426.57%. Given Seres Therapeutics' higher possible upside, analysts clearly believe Seres Therapeutics is more favorable than Erasca.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Erasca 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Seres Therapeutics 2 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.75 Is ERAS or MCRB more profitable? Erasca's return on equity of -36.56% beat Seres Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ErascaN/A -36.56% -31.08% Seres Therapeutics N/A -41,084.76%-55.87% Which has better valuation and earnings, ERAS or MCRB? Seres Therapeutics has higher revenue and earnings than Erasca. Seres Therapeutics is trading at a lower price-to-earnings ratio than Erasca, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioErascaN/AN/A-$161.65M-$0.62-2.24Seres Therapeutics$126.32M0.97$140K-$4.60-3.04 SummaryErasca beats Seres Therapeutics on 9 of the 14 factors compared between the two stocks. Get Seres Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MCRB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MCRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MCRB vs. The Competition Export to ExcelMetricSeres TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$124.52M$3.00B$5.48B$9.51BDividend YieldN/A2.43%4.73%4.08%P/E Ratio-3.0417.6228.6723.80Price / Sales0.97179.18373.9066.65Price / CashN/A41.9535.4557.96Price / Book8.698.508.275.55Net Income$140K-$55.06M$3.24B$259.03M7 Day Performance-3.72%-3.98%-3.69%-4.59%1 Month Performance28.82%9.59%4.33%4.46%1 Year Performance-44.04%6.72%25.95%18.03% Seres Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MCRBSeres Therapeutics2.9283 of 5 stars$13.99-1.9%$73.67+426.6%-44.5%$124.52M$126.32M-3.04330News CoverageUpcoming EarningsERASErasca2.0736 of 5 stars$1.70-2.3%$4.57+168.9%-54.7%$492.92MN/A-2.74120News CoverageGap DownMBXMBX Biosciences2.6288 of 5 stars$14.55-0.1%$37.57+158.2%N/A$486.32MN/A0.0036CGEMCullinan Therapeutics1.6 of 5 stars$8.23+0.6%$30.00+264.5%-59.1%$482.74MN/A-2.8330News CoverageUpcoming EarningsKODKodiak Sciences3.3197 of 5 stars$8.24-6.8%$9.00+9.2%+130.1%$466.43MN/A-2.2790Gap DownPGENPrecigen3.9979 of 5 stars$1.58+0.6%$6.00+279.7%+16.8%$463.43M$3.92M-2.82190News CoveragePositive NewsOptions VolumePRTCPureTech Health1.427 of 5 stars$19.09+0.1%$45.00+135.8%-12.1%$458.15M$4.83M0.00100Gap DownRGNXREGENXBIO4.1235 of 5 stars$8.79-1.9%$31.63+259.8%-38.5%$449.44M$83.33M-2.83370News CoverageUpcoming EarningsGap DownSVRASavara1.4769 of 5 stars$2.66+3.1%$5.60+110.5%-43.0%$445.92MN/A-5.5420High Trading VolumeKMDAKamada4.488 of 5 stars$7.68-0.5%$13.00+69.3%+30.3%$443.94M$160.95M26.48360News CoverageGap UpCMPXCompass Therapeutics2.3779 of 5 stars$3.20+0.6%$12.67+295.8%+196.2%$439.74M$850K-7.8020Gap Down Related Companies and Tools Related Companies ERAS Competitors MBX Competitors CGEM Competitors KOD Competitors PGEN Competitors PRTC Competitors RGNX Competitors SVRA Competitors KMDA Competitors CMPX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MCRB) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Seres Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Seres Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MCRB Stock Alerts